Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Citi: Ph2a Data of ASCLETIS-B's ASC30 Further Demonstrates Best-in-Class Potential & Superior Tolerability
Recommend 3 Positive 8 Negative 5 |
||||
|
||||
|
ASCLETIS-B (01672.HK) has announced positive data from its US Ph2a study of its oral GLP-1 drug ASC30 for the treatment of obesity, according to a report from Citi. After placebo adjustment, the weight reduction at week 13 for the ASC30 20mg/ 40mg/ 60mg dosage groups was 5.4%/ 7%/ 7.7%, with the medium/high dosage groups outperforming Citi's expectations (weight reduction >6.5%). Neither liver safety signals nor any elevations in ALT/ AST/ TBL were found in the study. Under the weekly incremental dosing regimen, the drug showed good tolerability. The discontinuation rates due to adverse events for the 20mg/ 40mg/ 60mg dosage groups were only 7.3%/ 7.5%/ 0%, making it the best among similar drugs. Citi believes these data further demonstrate ASC30's best-in-class potential and enhance confidence in future collaborations. Expecting a positive stock price reaction, the broker reiterated a Buy/High Risk rating for ASCLETIS-B, with a target price of HKD32. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
